Mingyu Chung, PhD
Min received his B.S. in Electrical Engineering at the University of Michigan and worked for five years as a product engineer at Samsung Austin Semiconductor. He received his Ph.D. in Chemical and Systems Biology at Stanford University, where he researched growth factor and cell cycle signaling in the laboratory of Tobias Meyer. He completed his postdoctoral training at Stanford University (laboratory of Thomas Rando), where he leveraged single-cell genomics and chemical and genetic screening to investigate the mechanisms of skeletal muscle stem cell fate specification. Min received an NIH F32 postdoctoral fellowship and is a co-author on 17 publications.
Learn more about Min
LinkedIn
Trang Vuong
Trang joined Juvena Therapeutics as a Scientist to contribute to Dr. Li’s research on developing various assays for advancing Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.
Trang obtained her undergraduate degree in Biochemistry and Molecular Biology from UC Davis and continued to study for her Master in Immunology at UC Davis. Before joining Juvena, she worked at Teva Pharmaceuticals and worked extensively in their antibody screening. She managed an early antibody discovery project and had experiences in running various animal models for lead efficacy testing. She has extensive experience in flow cytometry, assay development and project leadership.
Learn more about Trang
Elizabeth Neyens, PhD
With 20 years of experience as a Board-certified toxicological pathologist and a DVM, Dr. Elizabeth Neyens has dedicated their career to advancing drug development. They began as a staff pathologist at Merck and Charles River Preclinical Drug Development, followed by serving as Head of Pathology at Baxter in Europe. During a pivotal year in Israel, she worked as a consultant, supporting an IPO transition, before returning to North America to become a Professor of Pathology at Einstein Medical University in New York.
A recognized expert in biologics, Elizabeth played a advisory role in guiding the preclinical pipeline for JUV-161. Her professional focus lies in delivering GLP-compliant preclinical development programs, conducting peer reviews, and supporting successful IND submissions. Driven by a passion for translating innovative molecules into clinical success, they are committed to making global healthcare advancements accessible to patients worldwide.
Learn more about Elizabeth
EARD 2022: Mapping Secreted Proteins to Unmet Medical Needs by Dr. Thach Mai at Juvena August 2022
Skanda Goudar
Skanda joined Juvena Therapeutics in April 2025 as Senior Director of Alliance and Program Management. With 20 years of industry experience drawing from a solid clinical development background, across multiple therapeutic areas, all phases and FDA filings, he is adept at fostering effective collaborations to guide cross-functional teams in translating strategic plans into tactical initiatives. Most recently, heading the Alliance Management function at Bolt Biotherapeutics, he spearheaded the creation of effective solutions to bridge the cultural gap between biotech and big pharma, while adapting to the unique challenges of virtual team interactions, ensuring that market trends, competitive intelligence, and business analysis inform key decisions. Prior to that, he was Gilead Sciences managing a portfolio of partnerships and collaborations across R&D and Commercial, with a focus on oncology (immunotherapy) and antiviral development and commercialization. He has an MBA from Loyola Marymount University. In his free time, he enjoys reading (and writing) science fiction and exploring the great outdoors
Learn more about Skanda
CEO Hanadie Yousef was honored to represent Juvena Therapeutics at BIO International Convention in June 2022, where she gave a Company Presentation at the emerging company showcase. She had numerous meetings with exciting companies and investors focused on partnerships and was all around inspired by the exceptional attendees, sponsors, and organizers. Thanks to The National Institutes of Health for sponsoring the Innovation Zone and Juvena’s attendance
JOSEPH MILETICH, MD, PHD
Joseph Miletich, MD, PhD, is a former SVP, Research Sciences, at Merck. He has more than 20 years of combined experience at Merck and Amgen leading programs through Discovery Research, Preclinical Development and Translational Medicine/Early Development. At both companies, Dr. Miletich focused on building teams and investing in technologies, partnerships and acquisitions to enable capitalizing on new insights into biology regardless of therapeutic area or modality. Dr. Miletech currently serves as advisor and board director to several companies and firms. Most recently, Dr. Miletich was Merck Research Laboratories’ senior vice president of research sciences and is currently senior scientific advisor to Merck’s CEO, an advisor to Recursion, and a director to Flame Biosciences, among other roles. . Prior to his last 8+ years at Merck Research Laboratories, Dr. Miletich served as senior vice president of research and development at Amgen.
Dr. Miletich received his M.D. and Ph.D. degrees from Washington University in St. Louis and pursued clinical training in internal medicine at the University of California in San Francisco. Subsequently he joined the faculty at Washington University, pursued subspecialty training in clinical hematology and in laboratory medicine, and developed a leading research effort in hemostasis and thrombosis. Over a 17 year career, he rose through the ranks to become Professor of Medicine and Pathology and Head of the Division of Laboratory Medicine at Washington University, in which capacity he was responsible for the combined laboratories of the Barnes-Jewish Hospital system, one of the nation’s largest clinical laboratories.
Learn more about Joseph
John W. Day, MD, PhD
Since 2011 John has been Professor of Neurology, Pediatrics (Genetics) and Pathology at Stanford University, where he is Director of the Division of Neuromuscular Medicine. He received his MD from the University of Minnesota, and PhD in Neuroscience from Albert Einstein College of Medicine, where he studied neuronal electrophysiology, synaptic physiology and plasticity. After completing neurology and neuromuscular training at UCSF, he was Professor of Neurology, Pediatrics and Genetics at the University of Minnesota, where he founded and directed the Paul and Sheila Wellstone Muscular Dystrophy Center.
John has investigated the genetic causes and multisystemic effects of neuromuscular disorders and has more than 35 years of experience designing and directing clinical trials of novel therapeutics. He spearheaded clinical research on spinal muscular atrophy (SMA) at Stanford, which resulted in the approval of antisense and AAV-gene replacement treatments, and led to nationwide newborn screening for SMA and institution of neonatal genetic treatment.
Learn more about John
Tina Duong PT, PHD
Tina Duong is the Director of clinical outcomes research and development at Stanford University Neuromuscular division. Clinically, she is a physical therapist with 20 years of clinical experience in evaluating, treating and validating clinical outcomes for patients with neuromuscular disease.
Her clinical and research interests are in developing, refining and understanding impacts of muscle imbalances and pathology on function and performance. Her work has contributed to improved understanding and characterization of disease phenotypes impacting clinical trial design and care management.
Currently, her research focuses on the effect of exercise and physical activity on human movement and disease physiology. She hopes to integrate technology and digital biomarkers as a complementary tool to performance based measures used in trials, in the clinic and remotely. She enjoys working on collaborative diverse inter-disciplinary teams, mentorship and creating patient focused solutions to improve the quality of life for individuals with neuromuscular disease.
Learn more about Tina
